PubmedID,Title,Publication Date,Non-academic Author(s),Company Affiliation(s),Corresponding Author Email
34083781,Interleukins in cancer: from biology to therapy.,01-08-2021,Endres Stefan; Kobold Sebastian,and Division of Clinical; r Klinische,sebastian.kobold@med.uni-muenchen.de.
33667368,An expanded universe of cancer targets.,04-03-2021,Kim William; Tamayo Pablo,Center for Novel,william_hahn@dfci.harvard.edu.
36307055,Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.,01-01-2023,Loibl S,GBG Forschungs,None
35623341,Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.,13-06-2022,Berry Donald A,Berry Consultants,denise.wolf@ucsf.edu.
33157048,Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade.,14-12-2020,Carroll Susheela,Calithera Biosciences,motzerr@mskcc.org.
39366934,The genomic and transcriptomic landscape of metastastic urothelial cancer.,04-10-2024,Bieche Ivan,Faculty of,yohann.loriot@gustaveroussy.fr.
31039111,Management algorithms for metastatic prostate cancer.,01-02-2020,Park-Wyllie Laura; Hew Huong; McLeod Deanna,Janssen; Kaleidoscope Strategic,None
